LifeMD Q2 revenue misses estimates as shift to branded GLP-1 therapies weighs
LFMD•Outlook cut for 2026
LifeMD said it sees third-quarter 2026 revenue of $48 million to $51 million and expects third-quarter 2026 adjusted EBITDA between negative $1 million and positive $2 million.
The company revised its 2026 revenue guidance to $205.5 million to $212.5 million, down from $220 million to $230 million.
Key figures and analyst view
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Miss | $47.30 mln | $49.15 mln (8 Analysts) |
| Q2 Adjusted EBITDA | Miss | -$3.50 mln | -$340,500 (8 Analysts) |
| Q2 Gross Margin | 89% |
The current average analyst rating on the shares is buy, with 8 strong buy or buy recommendations, and no hold, sell or strong sell ratings. The average consensus recommendation for the advanced medical equipment and technology peer group is buy.
Wall Street's median 12-month price target for LifeMD Inc is $10.00, about above its August 4 closing price of .
